Literature DB >> 8456961

ANP kinetics in normal men: in vivo measurement by a tracer method and correlation with sodium intake.

G Iervasi1, A Clerico, S Berti, A Pilo, F Vitek, A Biagini, M T Baratto, R Bianchi, L Donato.   

Abstract

125I-labeled atrial natriuretic peptide (ANP) was bolus injected into seven healthy human male subjects on an unrestricted diet (sodium intake ranging from 80 to 300 mmol/day). A high-performance liquid chromatographic procedure was used to purify the labeled hormone and the principal labeled metabolites in venous plasma samples collected up to 50 min after injection. The main ANP kinetic parameters were derived from the disappearance curves of the 125I-ANP, which were satisfactorily fitted by a biexponential function in all subjects. Newly produced ANP initially distributes in a large space (plasma-equivalent volume is 12.1 +/- 3.6 l/m2 body surface); the hormone rapidly leaves this sampling space through both degradation and distribution in peripheral spaces, as indicated by the single-pass mean transit time through the sampling space (3.9 +/- 1.2 min). The mean residence time in the body (22.7 +/- 23.1 min) and the plasma-equivalent total distribution volume (30.9 +/- 12.0 l/m2) indicate that ANP is also widely distributed outside the initial space. Metabolic clearance rate (MCR) values were distributed across a wide range (from 740 to 2,581 ml.min-1 x m-2) and were shown to correlate strongly with the daily urinary excretion of sodium. These results indicate that: 1) newly produced ANP is rapidly distributed and degraded, 2) the body pool of the hormone can be considered as a combination of two exchanging spaces, 3) circulating ANP is < or = 1/15 of the body pool, and 4) MCR of ANP is closely related to sodium intake, at least in normal subjects on a free sodium intake diet.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8456961     DOI: 10.1152/ajprenal.1993.264.3.F480

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  6 in total

1.  Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure.

Authors:  A Clerico; G Iervasi; M G Del Chicca; M Emdin; S Maffei; M Nannipieri; L Sabatino; F Forini; C Manfredi; L Donato
Journal:  J Endocrinol Invest       Date:  1998-03       Impact factor: 4.256

2.  Circulating levels of cardiac natriuretic hormones measured in women during menstrual cycle.

Authors:  S Maffei; A Clerico; G Iervasi; M Nannipieri; S Del Ry; D Giannessi; L Donato
Journal:  J Endocrinol Invest       Date:  1999-01       Impact factor: 4.256

3.  Clinical relevance of cardiac natriuretic peptides measured by means of competitive and non-competitive immunoassay methods in patients with renal failure on chronic hemodialysis.

Authors:  A Clerico; R Caprioli; S Del Ry; D Giannessi
Journal:  J Endocrinol Invest       Date:  2001-01       Impact factor: 4.256

4.  A rapid procedure for the quantitation of natriuretic peptide RNAs by competitive RT-PCR in congenital heart defects.

Authors:  M R Iascone; S Vittorini; A Collavoli; A Cupelli; G Kraft; A Biagini; A Clerico
Journal:  J Endocrinol Invest       Date:  1999-12       Impact factor: 4.256

5.  In vivo measurement of ANP overall turnover and identification of its main metabolic pathways under steady state conditions in humans.

Authors:  A Clerico; G Iervasi; S Berti; A Pilo; F Vitek; S Salvadori; M Marastoni; C Manfredi; M G Del Chicca; M R Iascone
Journal:  J Endocrinol Invest       Date:  1995-03       Impact factor: 4.256

6.  Preparation of mono-radioiodinated tracers for study of the in vivo metabolism of atrial natriuretic peptide in humans.

Authors:  A Clerico; G Iervasi; C Manfredi; S Salvadori; M Marastoni; M G Del Chicca; D Giannessi; S Del Ry; M G Andreassi; L Sabatino
Journal:  Eur J Nucl Med       Date:  1995-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.